About
AI Drug Discovery
Areas of Focus
Categories
Small Molecule PharmaceuticalAI Focused
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
9
As Collaborator
3
Total Enrollment
968
By Phase
PHASE3: 2PHASE2: 5PHASE1/PHASE2: 1PHASE1: 2EARLY_PHASE1: 2
By Status
COMPLETED: 8UNKNOWN: 3TERMINATED: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT04106557Lead Sponsor
A Study of OV101 in Individuals With Angelman Syndrome (AS)
PHASE3Completed
104 participants
Started: Sep 9, 2019 · Completed: Nov 2, 2020
NCT03882918Lead Sponsor
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
PHASE3Terminated
141 participants
Started: Jan 31, 2019 · Completed: Jun 30, 2021
NCT03697161Lead Sponsor
A Study of OV101 in Individuals With Fragile X Syndrome
PHASE2Completed
36 participants
Started: Sep 17, 2018 · Completed: Feb 26, 2020
NCT03694275Collaborator
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
PHASE2Completed
20 participants
Started: Sep 10, 2018 · Completed: Jul 31, 2020
NCT03650452Collaborator
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
PHASE2Completed
141 participants
Started: Aug 8, 2018 · Completed: Jul 20, 2020
Locations (1)
Headquarters
Cambridge, UK
Map
Loading map...